Lindsay Fischer


Front-line maintenance with avelumab found efficacious for locally advanced, metastatic mUC

The real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Jason Harris


Expert highlights the latest radiotherapy developments in prostate cancer

“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.

Caitlin Delaney, MD


Physician Burnout: Assessing and addressing its impact on your family

“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.

Silas Inman


Rucaparib improves rPFS over Physician's Choice for BRCA+ mCRPC

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

Amanda Wager, Esq


Malpractice Consult: Affidavits of merit and why they matter

Most states require affidavits for malpractice cases to proceed.

Brenda Heath, RN


EP. 4B: The Effect of Leuprolide Formulations on Organizational Management Practices in Metastatic Prostate Cancer

In this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.

Christine Van Horn, MD


Quiz: Testicular trauma in 21-year-old

A 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.

Mark Schuster, MD, PhD


Expert emphasizes significance of physician self-care

If you’re a doctor, your job is to take care of others. But too often, that comes at the expense of taking care of yourself.

Judd Moul, MD


Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence 

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

Urology Times contributor


A urologist on why the time is right to let go

"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.

Jaret Shook


PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Scott D. Lundy MD, PhD


Male sexual health and reproductive medicine: All that glitters is not gold

"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.

Tony Berberabe, MPH


Study shows QoL sustained with mitomycin gel in low-grade NMIBC

The investigators concluded that a phase 3 trial is warranted.

Kristie Kahl


Conservative management feasible for uncomplicated renal colic patients with positive urine cultures

“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.

Jeremy D. Handel, MD


Case review: An incidentally discovered renal mass

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

Hayley Virgil


NCCN adds flotufolastat F 18 to prostate cancer guidelines

Flotufolastat F 18 is now included in the NCCN prostate cancer guideline recommendations for all the same categories as the other PSMA-PET imaging agents approved by the FDA.

Sabrina Serani


Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients

A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.

Allegheny Health Network


AHN Cancer Institute, Illumina to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient’s cancer, which may influence choice of treatment based on cancer stage and type.

Paul Sieber, MD


Key Challenges in the Administration of Leuprolide for Advanced/Metastatic Prostate Cancer

In the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.

Raoul S. Concepcion, MD, FACS


The urologist in the world of precision medicine

"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.

Stephanie Gleicher, MD, MPH


The status and future direction of advanced urine testing: multiplex PCR

"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.

Eman A. Elkadry, MD


EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.

Bob Kronemyer


Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder

“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.

Courtney Flaherty


Combo of sacituzumab govitecan and enfortumab vedotin shows potential in urothelial carcinoma

Combining the antibody-drug conjugates sacituzumab govitecan and enfortumab vedotin was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.

Jessica Skarzynski


Darolutamide safety in nmCRPC sustained with prolonged exposure

Safety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.

Morgan Petronelli


Study assesses impact of health literacy on chronic pelvic pain

Addressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.

Austin Ward


Automated medical coding benefits both the practice and the patients

When you add automation, your medical coding not only improves your margins but also plays a key role in improving patient care.

Paul E. Dato, MD


Treating mCRPC as a Multidisciplinary Team

In this installment, expert Paul E. Dato, MD, discusses the value of a multidisciplinary team in managing patients with mCRPC and considers how his institution ensures patients receive best available therapy.

Lourdes Guerrios Rivera, MD, MSc


What the SWIU Census reveals about the state of women in urology

"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.

Denise Juhr


Urologic research and COVID-19: Unmasking the silver lining

In this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.

© 2023 MJH Life Sciences

All rights reserved.